For clinical trials · CLIA-validated panel
Cognilera® for clinical trials: Alzheimer’s pathology and neuronal injury from one blood draw
Cognilera, developed by NeuroDex, measures p-Tau217, the Aβ42/40 ratio, GFAP and NfL from a single blood draw in a CLIA-certified laboratory. Trial teams can use these validated markers to characterize Alzheimer’s pathology in participants at baseline and to follow neuronal injury across visits.
- 4 markersOne drawp-Tau217, Aβ42/40 ratio, GFAP and NfL.
- ≤14 daysReport turnaroundTiered, flagged and reviewed by the laboratory director.
- CLIAValidated, locked protocolAutomated clinical immunoassay platforms with QC on every run.
How trial teams use Cognilera
One panel for participant characterization in cognitive studies
01
Characterize Alzheimer’s pathology
A blood-based read on Alzheimer’s pathology at baseline. In NeuroDex internal validation against amyloid PET, p-Tau217 showed 96% sensitivity and 97% specificity (11% indeterminate).
p-Tau217 · Aβ42/40 ratio
02
Follow neuronal injury across visits
Markers of neuronal injury and astrocyte activation from routine plasma, with every result reported against reference intervals and decision limits.
NfL · GFAP
03
Add brain-derived biomarkers
Pair the panel with NeuroDex’s brain-derived vesicle assays for TDP-43, α-synuclein and CNS target engagement in the same study.
Two panel options
Full panel
Cognilera® Complete
All four Tier 1 markers for Alzheimer’s pathology and neuronal injury, reported together in one result.
Cognilera CompleteFocused pathology test
Cognilera® p-Tau217
Plasma p-Tau217 on its own, when the question is narrow. Any p-Tau217 result can be extended to Complete on the same specimen.
Cognilera p-Tau217The core panel: Alzheimer’s pathology and neuronal injury
Tier 1 — Detect
Alzheimer’s pathology (p-Tau217, Aβ42/40 ratio) and neuronal injury and astrocyte activation (NfL, GFAP).
Specimen and site logistics
Add Cognilera to your next cognitive study.
Important information. Cognilera tests are laboratory-developed tests performed by SBH Diagnostics, 4 Strathmore Road, Natick, MA 01760 (CLIA #22D2060724). They have not been cleared or approved by the U.S. Food and Drug Administration. They are intended for adults under clinical evaluation for cognitive impairment and are not a screening test. Results should be interpreted by a qualified healthcare professional as one component of a clinical evaluation and are not a diagnosis on their own.
Performance figures are from NeuroDex internal validation. Alpha-synuclein and TDP-43 are in development and are not part of the reportable Cognilera panel. For clinical ordering, visit cognilera.com. Cognilera is a NeuroDex Inc. brand.

